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The aim of this study was to evaluate the efficacy and toxicity of low-dose methotrexate with folinic acid rescue in a large series of
consecutively treated patients with low-risk persistent gestational trophoblastic disease. Between January 1987 and December 2000,
250 patients were treated with intramuscular methotrexate (50mg on alternate days 1, 3, 5, 7) with folinic acid (7.5mg orally on
alternate days 2, 4, 6, 8) rescue. The overall complete response rate without recurrence was 72% for first-line treatment and 95% for
those who required second-line chemotherapy. Eight women (3.2%) had recurrence following remission and two (0.8%) had new
moles. Two women (0.8%) died of their disease giving an overall cure of 99%. Only 10 women (4%) experienced grade III/IV toxicity
during the first course of treatment and 13 women (5.2%) subsequently. Toxicity included mucositis and stomatitis, pleuritic chest
pain, thrombocytopenia, uterine bleeding, abdominal pain, liver function changes, rash and pericardial effusion. A total of 59 women
(23.6%) required second-line chemotherapy; 48 women had methotrexate resistance, eight had methotrexate toxicity and an
empirical decision to change therapy was made in three. In all, 11 women (4.4%) had a hysterectomy before, during or after
treatment; 141 women (56.4%) became pregnant following treatment: in 128 (90.7%), the outcome was successful. Methotrexate
with folinic acid rescue is an effective treatment for low-risk persistent trophoblastic disease. It has minimal severe toxicity, excellent
cure rates and does not appear to affect fertility.
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The gestational trophoblastic diseases are complications of
pregnancy and comprise a spectrum of conditions that
includes complete and partial hydatidiform mole, choriocarci-
noma and placental site trophoblastic tumour (PSTT). All have
the potential to persist and to metastasise to local or distant
structures.
The worldwide incidence of trophoblastic diseases ranges
between 0.5 and 8.3 cases per 1000 live births (WHO, 1983), with
the incidence in the UK of around 1.5 per 1000 births (Bagshawe
et al, 1986, Tham et al, 2003). In Sheffield, there are around 400
patients registered annually with a molar pregnancy. Most patients
have no further problems following evacuation of the mole, but
about 5% require chemotherapy for persistent disease (Sheridan
et al, 1993).
Low-dose methotrexate with folinic acid rescue, as described
by Bagshawe et al, (1989), has been the standard treatment
for ‘low-risk’ disease at the Sheffield Trophoblastic Tumour
Centre for many years. In 1987, we modified our approach so
that all patients who fell into the Charing Cross scoring
system ‘low’- and ‘medium’-risk groups (Newlands 1997) were
given low-dose methotrexate as first-line therapy. This study
reports on the efficacy and toxicity of treatment in this group of
patients.
PATIENTS AND METHODS
Sheffield is one of three supraregional screening centres and one of
two treatment centres in the UK for the registration, specialist
management and follow-up of gestational trophoblastic diseases.
All patients diagnosed with a molar pregnancy in Northern
England and North Wales (population approximately 22 million)
are registered at the Sheffield centre, but initially managed by their
local gynaecologist with uterine evacuation; hCG is monitored
regularly at Sheffield. Between January 1987 and December 2000,
5613 patients were registered; 250 patients were treated for low-
risk persistent trophoblastic disease. During the same period, 82
high-risk patients were treated with intensive multiagent therapy
(methotrexate alternating with etoposide and dactinomycin)
(Dobson et al, 2000).
The criteria for treatment of trophoblastic disease were:
1. hCG levels 420000 IUl
 1 after uterine evacuations;
2. Static or rising hCG levels after uterine evacuations;
3. Persistent uterine haemorrhage with elevated hCG level;
4. Persistent hCG elevation, 6 months after uterine evacuation;
5. Pulmonary metastases with static or rising hCG levels;
6. Metastases in liver, brain or gastrointestinal tract;
7. Histological diagnosis of true choriocarcinoma.
Patients were assessed at Weston Park Hospital with a
full history and physical examination, endocrine and bio-
chemical blood tests, full blood count, serum bhCG levels, Revised 22 September 2003; accepted 23 September 2003
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lhistopathological review of the products of evacuation, chest
radiograph, ultrasound of the pelvis and computerised tomogra-
phy of the thorax and upper abdomen. This information was
used to assign a risk score to each patient using the
Sheffield modification of the Charing Cross system (Table 1).
Patients were continued on chemotherapy for 6–8 weeks
after reaching complete remission (CR); that is, a normal
serum bhCG.
Low-risk patients received intramuscular methotrexate
50mg on alternate days (1, 3, 5, 7) with 7.5mg of oral folinic
acid rescue on alternate days (2, 4, 6, 8), 24h after the
methotrexate, with a 7-day break between courses. Strict
compliance was ensured by mandatory attendance at Weston
Park Hospital for all but a very few selected cases. The first
course of treatment was administered as in-patient therapy.
Serial serum bhCG values were measured as a basis for further
treatment. Patients who experienced severe toxicity or whose
bhCG levels had plateaued or were rising were changed to second-
line (intravenous) chemotherapy (Dobson et al, 2000), consisting
of etoposide and dactinomycin in combination, or methotrexate,
etoposide and dactinomycin in combination, or single-agent
dactinomycin.
Patients cured on first-line treatment alone were followed up for
a period of 5 years with blood and urine hCG analyses. Those who
went on to have second-line treatment or who had recurrent
disease are followed up for life.
The case notes and database records of all women treated with
first-line intramuscular low-dose methotrexate for low-risk
trophoblastic disease were studied. The following information
was collected: number of evacuations, time from evacuation to
treatment, pretreatment serum bhCG, site and number of
metastases, FIGO stage (FIGO, 1992) (Table 2), risk score, number
of cycles received, first course and subsequent toxicity according
to the ECOG Committee Toxicity Criteria (Oken et al, 1982),
reasons for change of treatment, outcome and post-treatment
fertility.
The clinical features of the patients are summarised in
Table 3. The age range was 15–57 years (median 27 years). The
median time from evacuation to treatment was 94 days (range
7–1149 days). The details of 28 women (11%) who were treated
for more than 6 months after evacuation are summarised in
Table 4. Four patients from this group required second-line
chemotherapy and one died. The range of serum bhCG levels
at assessment was 16–803000IUl
 1 (mean 23736). Outcome
was evaluated in all patients and toxicity in 244. At assessment,
178 patients (71.2%) had no detectable disease outside the uterus;
the other 72 (29%) had lung metastases only. The primary
indication for treatment was persistently elevated hCG level in
235 patients, vaginal bleeding in 14 and intra-abdominal bleeding
in one.
Table 1 Charing cross hospital prognostic scoring system
Variable 0 1 2 6
Age (years) p39 439
Antecedent pregnancy (AP) Mole Abortion/unknown Term
Interval between AP to treatment (months) hCG (IUl
 1) o4 4–6 7–12 412
10
3–10
4 o10
3 10
4–10
5 410
5
ABO blood group (female male) A OB  Oo rO
O AA B  Ao rO
Oo rA unknown
Number of metastases 1–4 4–8 48
Site of metastases Lungs, vagina Spleen, kidneys Gastrointestinal tract, liver Brain
Largest tumour mass o3cm 3–5cm 45cm
Previous chemotherapy Single drug Two or more drugs
hCG¼human chorionic gonadotrophin; Charing Cross System – low risk: 0 5, intermediate risk: 6 9, high risk: 49. Sheffield modification – low risk: 0 7, high risk: 47.
Table 2 FIGO (1992) staging system for gestational trophoblastic
disease (GTD)
Stage
I Disease confined to the uterus
II Beyond uterus but limited to genital structures
III To lungs with or without known genital tract involvement
IV Other metastatic sites
Sub stage
A No risk factor
B One risk factor
C Two risk factors
Risk factors
1. HCG4100000Ul
 1
2. Duration from termination of antecedent pregnancy
to diagnosis more than 6 months
Table 3 Clinical features of patients treated
Age (years)
p39 226 (90.4%)
439 24 (9.6)
Antecedent pregnancy
Mole 234 (93.6)
Term 1 (0.4%)
Termination 2 (0.8%)
Ectopic pregnancy 5 (4 molar ectopics,
1 not known) (2%)
Other (unspecified/no molar tissue) 8 (3.2%)
Evacuations
Mean 2.16
Median 2
Time from first evacuation to treatment (months)
o4 169 (67.6%)
4 6 51 (20.4%)
6 12 24 (9.6%)
412 4 (1.6%)
No evacuation 2 (0.8%)
bhCG (IUl
 1)
10
3 10
4 89 (35.6%)
o10
3 59 (23.6%)
10
4 10
5 95 (38%)
410
5 7 (2.8%)
Number of metastases
Nil 178 (71.2%)
1 4 53 (21.2%)
4 8 16 (6.4%)
48 2 (0.8%)
Unknown 1 (0.4%)
Methotrexate courses
Mean 8
Median 7
Range 1 14
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lRESULTS
Response to treatment
All patients received at least one full course of methotrexate (range
1–14, median 7). A total of 59 (23.6%) patients had second-line
salvage chemotherapy. All women have been followed up for at
least 1 year (range 1–16 years, median 5 years). Complete
remission with first-line methotrexate was achieved in 181 (72%)
patients. In those who had first- and second-line treatment, CR was
attained in 238 (95%). In all, 145 (81%) of 178 FIGO stage I
patients achieved CR with first-line treatment compared to 42
(60%) of 70 stage III patients (Table 4).
A total of 48 had methotrexate-resistant disease, eight had severe
methotrexate toxicity and an empirical decision to change
treatment was made in three. Of the eight patients with severe
toxicity, two developed abnormal liver function, one had severe
vaginal bleeding, three had pleuritic chest pain, one had abdominal
pain and one a pleural effusion.
The proportion of patients requiring second-line chemotherapy
increased with risk score, but this was not statistically significant
(Figure 1). Two patients (0.8%) had third-line treatment due to
resistant disease and metastases; both patients died of the disease.
The presenting risk scores in these two women were 4 and 7.
Following CR, eight women (3.2%) had recurrent disease and
two women (0.8%) had new moles. Three women had recurrence
within a year, four within 2 years and one within 3 years; six of
these patients had recurrence following first-line chemotherapy
and two patients had recurrence following first- and second-line
chemotherapy. Of the two women who had new moles, one had
two subsequent molar pregnancies and is thought to have a genetic
predisposition to molar pregnancies. The other woman had no
further pregnancies following her second mole. Neither woman
required chemotherapy for their subsequent molar pregnancies.
One patient died following a road traffic accident, in remission 3
years after finishing methotrexate chemotherapy. The overall
survival of all patients was 98%, with 247 patients alive and well.
In all, 17 (6.8%) women experienced delays during treatment;
six women defaulted treatment, 10 experienced toxicity (myelo-
suppression, severe bleeding, biochemical changes) and in one
there was no record of why treatment was delayed.
Toxicity
Toxicity was evaluated for the first and subsequent courses of
methotrexate (Table 5). A total of 158 (63.2%) women experienced
first course toxicity compared with 183 (73.2%) during subsequent
courses. In all, 10 women (4%) during the first course, and 13
women (5.2%) during subsequent courses, experienced grade III/
IV toxicity.
Haematological Two women (0.8%) had grade III/IV myelosup-
pression during the first course. Grade I/II and Grade III/IV
myelosuppression occurred during subsequent courses in four
(66%) and three (1.2%), respectively. There were no dose
reductions due to myelosuppression; however, four women had
treatment delays.
Other toxicities Blepharitis, conjunctivitis, stomatitis and muco-
sitis were the most common side effects. Only one woman during
the first course and two women during the subsequent courses
developed grade III/IV mucositis and stomatitis.
Pleuritic chest pain was also commonly experienced. Three
women (1.2%) had their treatment changed during subsequent
courses due to grade III/IV chest pain. One patient during the first
course and five patients during subsequent courses developed mild
Table 4 FIGO stage of patients treated with first-line and salvage
chemotherapy
FIGO stage
Number
of patients
Cured with first-
line treatment
Cured after salvage
chemotherapy
I 178 (71.25) 145 33
II 1 (0.4%) 1
III 70 (28.0%) 42 26
a
IV 0
Unknown 1 (0.4%) 1
aTwo patients died of chemoresistant disease.
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Figure 1 Number of patients cured with first-line treatment compared
with those needing second-line treatment, according to risk score.
Table 5 Side effects from methotrexate treatment
a
First course
of treatment
Subsequent
courses
Side effect Grade I/II Grade III/IV Grade I/II Grade III/IV
Anaemia 2 (0.8%)
Neutropenia 1 (0.4%) 1 (0.4%) 2 (0.8%)
Thrombocytopenia 1 (0.4%) 1 (0.4%) 1 (0.4%)
Nausea 19 (7.6%) 37 (14.8)
Vomiting 5 (2%) 12 (4.8%)
Abdominal pain 21 (8.4%) 2 (0.8%) 34 (1.6%) 1 (0.4%)
Abnormal liver function 1 (0.4%) 1 (0.4%) 3 (1.2%)
Mucositis/stomatitis 61 (24.4%) 1 (0.4%) 65 (26%) 2 (0.8%)
Sore/bleeding gums 2 (1.6%) 8 (3.2%)
Epistaxis 6 (2.4%) 3 (1.2%)
Blepharitis/conjunctivitis 61 (24.4%) 60 (24%)
Pleuritic chest pain 22 (8.8%) 60 (24%) 3 (1.2%)
Shortness of breath 1 (0.4%) 5 (2%)
Pleural effusion 1 (0.4%)
Skin rash 8 (3.2%) 1 (0.4%) 2 (0.8%) 1 (0.4%)
Vaginal bleeding 49 (19.6%) 4 (1.6%) 38 (15.2%) 2 (0.8%)
aIn all, 92 (36.8%) had no toxicity during their first course; 67 (26.8%) had no toxicity
during subsequent courses.
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lshortness of breath. Two of these patients had shortness of breath
associated with pleuritic chest pain. One woman developed a
pericardial effusion (Forbat et al, 1995).
In total, 49 women (19.6%) experienced grade I/II vaginal
bleeding during the first course and 38 women (15.2%) during
further courses. Four women during the first course and two
women during subsequent courses had grade III/IV bleeding.
Three (1.2%) women required hysterectomy during treatment.
Mild nausea was a common feature during both first and
subsequent courses. One woman had treatment changed due to
abdominal pain, thought to be due to peritoneal toxicity (Sharma
et al, 1999). Grade I/II epistaxis was noted for six women during
the first course and in three women during subsequent courses.
After course one, one woman had grade I/II liver function changes;
one woman had grade III/IV changes and was changed to second-
line treatment. Three women had grade I/II liver function changes
during further courses. One woman had a grade III/IV rash and
had her treatment changed. Alopecia did not occur.
Hysterectomy A total of 11 women (4.4%) had a hysterectomy
before, during or after treatment. Four women had uterine rupture
or severe bleeding before treatment, three women had severe
bleeding during treatment, and following treatment four women
had either irregular bleeding or fear of recurrence.
Long-term effects Following treatment, 141 women had one or
more further pregnant events; 128 (90.7%) of these were full-term
normal pregnancies. There were 21 miscarriages, 11 terminations
and one ectopic pregnancy. Only two women (0.8%) had new
molar pregnancies. There is no information on long-term fertility
status in 98 women (39.2%). There have been no recorded second
malignancies.
DISCUSSION
It is difficult to compare treatment results for persistent gestational
trophoblastic disease (GTD) across the world because of the
heterogeneity of patient groups selected for single- or multiagent
chemotherapy, and because of the wide variety in chemotherapy
regimens used. Part of the problem stems from the use of different
criteria by various centres for starting treatment and different
staging or prognostic scoring classifications. However, in general,
patients are selected for therapy on the basis of whether they have
metastatic disease and whether they are at low or high risk of
persistent or recurrent disease. Patients adjudged as low risk or
without metastases have usually been given single-agent regimens
(most often methotrexate or dactinomycin). It is hoped that there
will be further standardisation with the recent introduction of the
revised FIGO/WHO staging/scoring system (FIGO, 2002).
Since the initial experience of using methotrexate in the
treatment of trophoblastic disease in the 1950s, it has proved to
be an active agent with minimal severe toxicity in the treatment of
low-risk patients. Comparisons between various methotrexate
regimens and with alternative agents can be made (on efficacy,
toxicity and cost effectiveness), both in curing disease and
preserving fertility.
The UK has a more conservative approach to initiating
treatment for persistent disease than the US; 5–8% of UK and
up to 20% of US patients receive treatment. A widely used US
protocol recommends that if hCG levels increase or plateau over
three consecutive weeks, immediate assessment and treatment for
post molar disease are indicated (Berkowitz and Goldstein, 1996.
In the UK, treatment is expectant and patients may be followed
with serial hCG levels for up to 6 months (Gillespie et al, 2000). A
recent proposal is that persistent gestational trophoblastic
neoplasia should be diagnosed if the plateau of hCG lasts for 4
weeks or more, there is a rise of hCG on three consecutive weekly
measurements over a period of 2 weeks or longer, there is a
histological diagnosis of choriocarcinoma or the hCG level remains
elevated for 6 months or longer (FIGO, 2002). In the UK, each
course of chemotherapy is expected to give around a 50% decrease
in serum hCG levels. Further treatment is given until complete
remission and then for up to 8 weeks following. In contrast, in the
US uncomplicated cases, further treatment is often withheld after
the first course if the hCG is falling.
Goldstein et al (1998), in an evaluation of the revised FIGO
(1992) staging, concluded that single-agent chemotherapy is the
preferred therapy in patients with nonmetastatic GTD who desire
to preserve fertility, and that patients with low-risk metastatic
disease involving the pelvis with or without lung metastases (low-
risk FIGO stage II, III) also respond well. In total, 351 of 377 (95%)
of their FIGO stage I patients were cured by various different
single-agent (methotrexate or dactinomycin) regimens. Single-
agent chemotherapy also produced remissions in 55 out of 66
(87%) and 13 out of 17 (76%) of low- and medium-risk patients
with metastatic disease. Other authors have also reported
remission rates of over 80% for this group of patients (Dubeshter
et al, 1987; Ayhan et al, 1992; Dubuc-Lissoir et al, 1992).
For many years UK centres have used the low-dose intramus-
cular methotrexate regimen. Initial reports on 487 patients from
Charing Cross (Bagshawe et al, 1989) and 115 from Sheffield
(Dorreen et al, 1988) confirmed its efficacy, although it was noted
that up to 30% of patients needed second-line treatment due to
resistance or, less frequently, toxicity. In the recent Charing Cross
report of use of this regimen for low-/intermediate-risk patients,
33.2% of 485 patients required a change in treatment; however,
overall survival was 100% (McNeish et al, 2002).
Methotrexate by intravenous infusion has also been evaluated as
a treatment option. One protocol (Berkowitz et al, 1990)
administered 100mgm
 2 by intravenous infusion over 30min
followed by 200mgm
 2 over 12h. After 24h, 15mg of folinic acid
was given intravenously every 12h for four doses. In nonmetastatic
disease, CR was achieved in 68.7% of patients compared with
90.2% in patients on the 8-day intramuscular regimen. None of the
patients given methotrexate by infusion developed significant
biochemical toxicity. One patient developed a severe rash. On the
8-day regimen, 24.7% of patients developed side effects including
myelosuppression, pleurisy, nausea and vomiting and in particular
hepatotoxicity. In a more recent study, the methotrexate infusion
was given without folinic acid rescue in patients with or without
lung metastases (Wong et al, 2000). In all, 91.5% of patients
achieved CR on first-line therapy alone. Mild nausea affected five
patients and one woman had severe myelosuppression, rash,
stomatitis and pharyngitis, although interestingly, she had
nontoxic postinfusion methotrexate levels. In both these studies,
dactinomycin was added to subsequent infusions in patients with
resistant disease. However, both studies involved few patients (32
and 59, respectively); additionally, the amount of drug being
delivered by infusion was close to twice that given to patients on a
low-dose intramuscular methotrexate and folinic acid protocol.
Five-day methotrexate regimens (using both intramuscular or
intravenous routes) have also been evaluated (Soper et al, 1994;
Lurain and Elfstrand, 1995). For example, with 0.4mgkg
 1day
 1
intramuscularly for 5 days, repeated at 12–14 days, in 52 patients
with metastatic disease, 60% achieved primary remission; second-
line chemotherapy with single-agent dactinomycin resulted in an
overall 96% remission rate. A total of 20% of patients experienced
severe haematological toxicity or mucositis. A further 60% of
patients had mild toxicity including hepatotoxicity, serositis,
pleurisy or stomatitis.
Single-agent intravenous dactinomycin has also been used with
success in patients with and without metastases (Homesley, 1997).
One study (Schlaerth et al, 1984) showed a cure rate of 82.5% with
single-dose biweekly dactinomycin. Patients were changed to 5-
day actinomycin or 5-day methotrexate for resistance. Most
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lpatients had only mild side effects. Three patients had a rash,
two had mild liver function changes and three had thrombo-
cytopenia. Vomiting occurred in 57%. Treatment courses were
shorter and less costly in hospital in-patient time. In another
study, in nonmetastatic disease, single-dose intravenous
dactinomycin 1.25mgm
 2 gave a CR rate of 94%. Patients failing
to respond adequately were changed to 5-day dactinomycin
(Petrilli et al, 1987). However, these studies are small, with only
17 and 31 patients, respectively, being evaluated. Larger and
longer-term comparative studies will need to be carried out to
show superiority over methotrexate, particularly since dactinomy-
cin causes more myelosuppression, nausea and vomiting and
alopecia.
In the UK treatment is selected on the basis of risk score. When
treatment response was assessed in our low-risk patients,
according to whether they were metastatic or nonmetastatic, the
CR rate was 60% in the former and 81% in the latter group. The CR
rate for metastatic disease is lower than that reported in other
smaller series. However, there was no difference in final outcome
between these groups since the vast majority of methotrexate-
resistant patients responded to second-line chemotherapy (Dob-
son et al, 2000). For all patients, the initial CR rate of 72% and
overall 99% cure rate justifies the strategy of treating all low-/
medium-risk patients initially with single-agent methotrexate in
the knowledge that almost all who are resistant to this first-line
therapy can be salvaged with alternative or more intensive
regimens. We acknowledge that the etoposide component of our
second-line chemotherapy regimen potentially puts these patients
at risk of myelodysplastic disorders. Fortunately, we have not
observed this complication (Dobson et al, 2000); however, we have
recently changed our policy, in that methotrexate-failures with low
hCG levels now receive dactinomycin alone.
In conclusion, methotrexate achieves high CR rates for low-risk
persistent gestational trophoblastic disease. There are several
different protocols for treatment administration, but larger
comparative studies of their efficacy and toxicity, as well as
long-term outcome are needed. However, the UK experience with
low-dose intramuscular methotrexate is extensive (Dorreen et al,
1988; Bagshawe et al, 1989; McNeish et al, 2002) and this is a
relatively inexpensive and cost beneficial treatment (Hancock,
1997). Our study confirms the efficacy and relative lack of severe
short- and long-term toxicity of this regimen. Considering the
Charing Cross and Sheffield joint experience for all low-risk
patients treated in the UK (735 over 14 years), the cure rate
approaches 100%. There does not appear to be an increased risk of
second cancers, and fertility is preserved.
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